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Neutral endopeptidase inhibition potentiates the renal actions of atrial
natriuretic factor. Atrial natriuretic factor (ANF) is degraded by neutral
endopeptidase. We hypothesized that neutral endopeptidase inhibition
(NEP-I) increases sodium excretion and that this effect would be
potentiated in the presence of an isolated increase in intrarenal ANF. In
seven anesthetized dogs, ANF was infused into one renal artery to
produce pathophysiologic concentrations in the supplemented kidney
while the control kidney received physiologic circulating concentra-
tions of ANF. In the control kidney, NEP-I (SQ 28,603) produced
significant increases in urine flow, absolute sodium excretion and
fractional sodium excretion while glomerular filtration rate (GFR)
remained constant. These renal actions of NEP-I were associated with
marked increases in urinary excretion of ANF and cyclic GMP consis-
tent with decreased renal degradation and increased biologic activity of
ANF. All of these effects were significantly greater in the supplemented
kidney. The present study suggests that NEP-I produces natriuresis
which appears to be independent of changes in GFR. In addition, while
NEP-I mimics the renal action of pathophysiologic levels of ANF,
NEP-I also potentiates the natriuretic effects of pathophysiologic con-
centrations of ANF as observed in congestive heart failure or hyper-
tension.
Atrial natriuretic factor (ANF) is an endogenous peptide
hormone which under physiologic conditions is secreted in
response to distension of the cardiac atria [1]. ANF participates
in the regulation of body fluid homeostasis by enhancing sodium
excretion, inhibiting the renin-angiotensin-aldosterone system,
and decreasing cardiac filling pressures [2, 3]. Studies have
recently demonstrated that a major pathway for degradation of
ANF as well as other peptide hormones is by neutral endopep-
tidase 24.11 [4—61. This enzyme is localized principally within
brush border vesicles of renal proximal tubules [7—9]. Neutral
endopeptidase inhibition (NEP-I) may permit modulation of
peptide metabolism and increase our understanding of the
actions of endogenous peptides in physiologic and pathophysi-
ologic states.
Recent preliminary reports have investigated the effects of
NEP-! in states characterized by elevated circulating levels of
ANF including saline volume expansion, experimental hyper-
tension, congestive heart failure, and following administration
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of pharmacologic concentrations of synthetic ANF [10—18].
NEP-! consistently enhanced renal sodium and water excre-
tion, often in association with further increases in circulating
levels of ANF. These studies attributed the renal action of
NEP-I to the increases in circulating ANF produced by inhibi-
tion of intra- and extrarenal ANF degradation [13, 14, 16, 17].
These studies, however, failed to determine whether the renal
action was mediated by an increase in glomerular filtration rate
(GFR) and/or a decrease in tubular reabsorption. Moreover,
these studies did not address the ability of NEP-I to potentiate
the local action of ANF within the nephron independent of
changes in circulating ANF.
The current study was designed to determine the action of
NEP-I (SQ 28,603) upon bilateral renal hemodynamic and
excretory function in normal anesthetized dogs in which one
kidney was exposed to physiologic concentrations of ANF and
the contralateral kidney was infused with pathophysiologic
concentrations of ANF. This design tested the hypothesis that
NEP-I is natriuretic and that pathophysiologic concentrations
of ANF potentiate the renal tubular actions of NEP-I, thus
enhancing the natriuresis following NEP-I.
Methods
Surgical preparation
Experiments were conducted on seven mongrel dogs weigh-
ing 17 to 26 kg. All dogs were given lithium carbonate 300 mg
orally and fasted 16 to 20 hours prior to the experiment. Dogs
were permitted to drink water ad libitum until the time of the
experiments. Anesthesia was accomplished with pentobarbital
30 mg/kg with supplemental 65 mg doses given as needed
throughout the experiment. The animals were intubated and
mechanically ventilated (Harvard Respirator, Harvard Appara-
tus, Millis, Massachusetts, USA) with supplemental oxygen at
4 liters per minute. A femoral artery was cannulated for
monitoring of arterial pressure and blood sampling. Femoral
veins were cannulated for infusion of inulin and injection of the
NEP-I and supplemental anesthetic. A balloon-tipped, flow-
directed pulmonary artery catheter (Model 93-l2lA, 7 Fr.,
American Edwards Laboratories, Santa Ana, California, USA)
was placed via the right internal jugular vein for measurement
of cardiac filling pressures and determination of cardiac output
by thermodilution. Pulmonary capillary wedge pressure was
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Table 1. Cardiovascular and hormonal function before and after neu tral endopeptidase inhibition (NEP-I)
Baseline ANF NEP-I Recovery
MAP mm Hg
RAP mm Hg
PCWP mm Hg
CO liter/mm
SVRRU
PRA nglmllhr
ALDO ng/dl
PIANFpg/m!
122 5
—0.4 0.3
4.1 0.4
3.8 0.4
34.5 1.9
4.5 1.1
12.4 2.1
29 12
130 7
—0.8 0.3
3.7 0.4
2.7 0.2a
50.9 4.8a
2.3 0.?
14.6 3.047 1l
132 6
—0.9 0.2a
3.6 0.3
2.1 02a,b
65.0 55a,b
1.3 0.4a
13.3 3.0
87 25a.b
127 6
—1.3 o.2
3.3 0.51.7 o.277.6 54
2.3 0.5
13.7 3.9
33 6
All data are expressed as mean SEM, N = 7. Abbreviations are: ANF, atrial natriuretic factor; MAP, mean arterial pressure; RAP, right atrial
pressure; LAP, left atrial pressure; CO, cardiac output; SVR, systemic vascular resistance; RU, resistance units (mm Hg/mi/mm); PRA, plasma
renin activity; ALDO, plasma aldosterone; P1 ANF, plasma atrial natriuretic factor.
a p < 0.05 vs. baseline
bP < 0.05 pre-NEP-I vs. post-NEP-I
used to estimate left atrial pressure and right atrial pressure was
measured directly.
Bilateral flank incisions were performed to gain exposure to
both kidneys. Each ureter was cannulated for urine collection
and a non-cannulating electromagnetic flow probe (Carolina
Medical Electronics, King, North Carolina, USA) was placed
around each renal artery for on-line measurement of renal blood
flow. Curved 23-gauge needles, attached to polyvinyl tubing,
were inserted into each renal artery distal to the flow probe and
were kept patent by an infusion of 0.9% saline at 0.5 mllmin.
Experimental protocol
A priming dose of inulin was given, and a constant infusion of
1 mllmin was begun in an effort to achieve a steady-state plasma
level of approximately 70 mg/dl. Following a 60-minute equili-
bration period, 30-minute baseline renal clearances were per-
formed for each kidney. During this and subsequent clearance
periods, blood was drawn for hormonal analyses and determi-
nation of inulin, sodium, and lithium concentrations. Cardiac
output, mean arterial pressure, right and left atrial pressure,
renal blood flow, and urine flow were also measured during
each clearance period. Additional urine samples were collected
on ice for measurement of urinary ANF and unnary cyclic
guanosine monophosphate (cGMP), the latter a biologic marker
for renal ANF activity [19].
Following baseline measurements, an infusion of synthetic
a-human ANF (28 aa, Peninsula laboratories, Inc., Belmont,
California, USA) was begun at a rate of 2 ng/kg/min into the
right renal artery, while the left kidney received the saline
vehicle at the same rate. This rate was selected to produce
pathophysiologic levels of ANF in the supplemented kidney
(SK) without affecting systemic hemodynamics or renal func-
tion in the control kidney (CK). A second 30-minute renal
clearance was performed beginning 15 minutes after the ANF
infusion was begun in the SK. At the conclusion of this
clearance period, the NEP-I (SQ 28,603) was given intrave-
nously over two minutes at a dose of 30 mg/kg. SQ 28,603
(N-[2-(mercaptomethyl)- l-oxo-3-phenylpropyl]--alanine) is a
potent competitive inhibitor of neutral endopeptidase 24.11
with a K1 value of 1 nM. SQ 28,603 is selective in that it shows
only weak activity against two other renal brush border pepti-
dases: angiotensin converting enzyme (I = 32 sM) and ami-
nopeptidase M in which there was no inhibition at concentra-
tions up to I /M (Dalaney NO, unpublished data). A third
30-minute clearance period was started 15 minutes after the
NEP-! was given. Finally, the ANF infusion into the SK was
discontinued and a 30-minute recovery clearance was begun 15
minutes later. In all experiments, urinary fluid losses were
replaced with intravenous normal saline every 15 minutes.
Extracted arterial plasma levels of ANF and urinary ANF
levels were measured by radioimmunoassay to a-hANF as
previously described [20]. To calculate the increment in renal
ANF concentration in the SK produced by the ANF infusion,
the infusion rate was divided by the renal plasma flow. The
calculated plasma ANF concentration for the SK was obtained
by adding this number to the circulating arterial plasma ANF
level. Plasma renin activity was determined by radioimmuno-
assay using the method of Haber et al [21]. Plasma aldosterone
concentration was measured by specific radioimmunoassay [3].
Urinary cOMP was measured by radioimmunoassay using the
method of Steiner, Parker and Kipnis [22]. Plasma and urinary
sodium concentrations were measured using ion-selective elec-
trodes (Beckman Instruments, Brea, Louisiana, USA), and
plasma and urine lithium levels were determined by flame-
emission spectrophotometry (Model 357, Instrumentation Lab-
oratory, Wilmington, Massachusetts, USA). Glomerular filtra-
tion rate (GFR) was determined by inulin clearance. Plasma and
urine inulin concentrations were determined by the anthrone
method [231. Cardiac output was determined by thermodilution
(Cardiac Output model 9510-A computer, American Edwards
Laboratories, Irvine, California, USA). Systemic vascular re-
sistance was calculated by dividing cardiac output by the
difference between mean arterial and right atrial pressures.
Renal filtration fraction was determined by dividing GFR by
renal plasma flow after assuming the hematocrit was stable at
45%.
All data are presented as mean standard error. Within
group comparisons with baseline and before and after NEP-I
were made using analysis of variance for repeated measures and
Scheffe's multiple comparisons test. Comparisons between SK
and CK were analyzed by one-way analysis of variance fol-
lowed by paired Student's t-test. Statistical significance was
defined as P < 0.05.
Results
The systemic hemodynamic and hormonal responses ob-
served during the experimental protocol are presented in Table
1, and the renal hemodynamic and excretory responses are
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Table 2. Renal hemodynamic and excretory function in supplemented and control kidneys before and after neutral endopeptidase inhibition
Baseline ANF NEP-! Recovery
Control kidney
GFR mi/mm 29.5 2.6 28.8 2.3 30.4 1.8 23.9 3.1
RBF mi/mm 251 28 211 25 161 2l 167 l4
RVRRU 0.53 0.07 0.68 0.10 0.94 0.l6c 0.79 0.05
U Osm mOsm/liter 1176 254 974 192 631 96 946 182
UV mi/mm 0.23 0.05 0.43 0.13 0.92 0.27 0.43 0.17
UNaV p.Eq/min 46 11 85 29 156 43 75 21
FEND % 1.12 0.27 1.93 0.53 3.43 076 2.03 0.41
FELI% 41±7 46±7 44±6 40±6
UANFV pg/mm
FEANF %
43 14
8 3
84 45
6 3
579 l3OaC28 5al 297 5430 3
UCGMPV pmoi/min 499 76 605 79 979 l34C 546 193
Filtration fraction % 0.23 0.04 0.27 0.03 0.38 0.05 0.26 0.02
ANF pg/mi 29 12 47 l1 87 25a,c,d 33 6
Supplemented kidney
GFR mi/mm 29.5 2.8 35.1 2.5aI 373 33b 26.5 3.6
RBF mi/mm 206 16 190 28 182 33 165 34
RVRRU 0.62 0.07 0.82 0.16 0.91 0.18 1.01 0.22
U Osm mOsm//itcr 1106 175 491 42' 346 32" 592 l04al
UV mi/mm 0,25 0.05 1.18 0.23' 2.94 0.49e 0.81 024a,b
UNaV pEq/min
FENa %
52 13
1.18 0.22
199 44
3.95 0,78a
410 87a,b.c
7.50 1.2l' 125 25a,b3.29 041a,b
FELl %
UANFV pg/mm
FEANF%
UCGMPV pmoi/min
Filtration fraction %
35 741 98 2
624 53
0.27 0.03
50 7
273 208
a.b
724 55
0.38 0.06°"
59 10
2592 1203a,b.c
11 5C
1404 179a.b.c
0.44 0.06a
46 10
444 16838 6
819 234
0.36 0.09
ANF pg/mP 29 12 517 73a.b 601 33 6
All data are expressed as mean SEM, N = 7. Abbreviations are: ANF, atrial natriuretic factor; NEP-I, neutral endopeptidase inhibition; GFR,
glomerular filtration rate; RBF, renal blood flow; RVR, renal vascular resistance; U Osm, urine osmolality; UV, urine flow; UNV, absolute sodium
excretion; FENa, fractional excretion of sodium; FELl, fractional excretion of lithium; UANFV, absolute ANF excretion; FEANF, fractional
excretion of ANF; UCGMPV, absolute cGMP excretion.
a P < 0.05 vs. baseline
b p < 0.05 supplemented kidney vs. control kidney
P < 0.05 pre-NEP-I vs. post-NEP-I
d P < 0.05 control kidney NEP-I vs. supplemented kidney ANF
Calculated renal plasma ANF (Methods)
presented in Table 2. During ANF infusion the calculated
plasma ANF levels in the SK, in excess of 500 pglml, were in
the high pathophysiologic range. The small but significant
increase in circulating arterial plasma ANF from 29 12 to 47
11 suggested some spillover into the systemic circulation. In
addition, right atrial pressure and cardiac output decreased
while mean arterial pressure and systemic vascular resistance
increased. Plasma renin activity also decreased significantly
during the ANF infusion. The renal responses of the SK to
pathophysiologic concentrations of ANF included significant
increases in GFR, filtration fraction, urine flow, absolute so-
dium excretion (UNaV), fractional sodium excretion (FENa),
and fractional lithium excretion (FELl). Significant decreases in
urine osmolality and fractional excretion of ANF were ob-
served in the SK during ANF infusion. No significant changes
in the renal function of the CK were observed during this
period.
With intravenous administration of NEP-I, systemic plasma
ANF increased from 47 11 to 87 25 pg/mI (P < 0.05) despite
no change in left or right atrial pressures and no change in mean
arterial pressure. Cardiac output decreased and systemic vas-
cular resistance increased while other systemic hemodynamic
and hormonal parameters did not change following NEP-!.
NEP-I produced substantial changes in renal function in both
kidneys. In the CK, GFR was unchanged, renal blood flow and
urine osmolality decreased, and urine flow, UNaV, FENa,
filtration fraction and renal vascular resistance increased. Uri-
nary cGMP excretion increased significantly compared with
baseline, and marked increases in absolute and fractional ex-
cretion of ANF were observed. Of note, except for the in-
creases in ANF excretion and the relatively smaller decrease in
urine osmolality, the renal responses in the CK following NEP-I
did not differ significantly from those observed in the SK during
ANF administration despite markedly different renal plasma
concentrations of ANF.
In the SK, receiving pathophysiologic concentrations of
ANF, GFR and renal blood flow were unchanged. However,
marked increases in urine flow, UNaV and FENa were observed
following NEP-I and were significantly greater than those
observed in the CK which received physiologic circulating
concentrations of ANF (Fig. 1). These increases in sodium and
water excretion in the SK were associated with marked in-
creases in fractional excretion of ANF and urinary cGMP
excretion. The increases in urine flow, UNaV, FENa, absolute
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ANF excretion, and cGMP excretion in the SK were all
significantly greater than the corresponding increases observed
in the CK following NEP-I administration.
Discussion
This study demonstrates that an inhibitor of neutral endopep-
tidase (SQ 28,603) produced increases in urine flow and abso-
lute and fractional sodium excretion in normal anesthetized
dogs. The natriuresis which occurred following NEP-I admin-
istration was accompanied by small but significant increases in
plasma ANF. These increases in sodium and water excretion
occurred in the absence of any significant increases in either
GFR or renal blood flow, indicating that a decrease in tubular
sodium reabsorption was probably responsible for the observed
natriuresis. Although NEP-! may have also interfered with both
the intrarenal and systemic degradation of peptides other than
ANF, the potentiated natriuresis associated with increased
urinary excretion of cGMP in the presence of pathophysiologic
concentrations of ANF suggests that the renal natriuretic action
of NEP-I may be due to inhibition of the renal inactivation of
ANF.
The effect of NEP-I on urine flow and sodium excretion in the
normal animal is not clearly defined. In normal conscious rats,
Koepke et al [13] reported no effect of endopeptidase inhibition
with thiorphan on sodium excretion, in contrast to two prelim-
inary studies reporting thiorphan-induced natriuresis in normal
anesthetized rats [10, 12]. Phosphoramidon, another NEP-I,
also induced natriuresis and diuresis in anesthetized rats [24].
The present study demonstrates, for the first time, that NEP-I
in the anesthetized dog also produces both natriuresis and
diuresis, Although the present study was performed in the
presence of anesthesia, a recent study by Northridge et al [14]
observed natriuresis following administration of an orally-
active NEP-I (UK 69,578) in normal conscious humans. More-
over, in preliminary studies on conscious mice, Samuels et al
[25] observed that NEP-I (UK 79,300) produced diuresis and
natriuresis during the first hour after its administration. Thus,
the data from the current and other published studies indicate
that NEP-I results in natriuresis and diuresis in several normal
species. To date, however, these recent studies failed to define
whether the natriuretic action was mediated by a renal hemo-
dynamic or tubular action of neutral endopeptidase inhibition.
In the current study, NEP-I in the presence of physiologic
concentrations of ANF resulted in significant increases in
plasma ANF. The increases in circulating ANF were small and
remained within the physiologic range. Previous reports suggest
some inconsistency in the ability of NEP-I to increase plasma
ANF levels. Samuels et al [25] reported a doubling of plasma
ANF following administration of NEP-I (UK 79,300) in normal
mice, and Northridge et al [14] reported similar results follow-
ing NEP-I (UK 69,578) in normal humans. In contrast, Koepke
et al [13] and Olins et al [26] found thiorphan increased plasma
ANF levels in conscious rats only when pharmacologic concen-
trations of ANF were administered concomitantly. These dis-
crepancies could be due to differences in the NEP-I used, to
species differences, or to more subtle differences in experimen-
tal design. In the present study, circulating ANF increased
despite significant decreases in left and right atrial pressures
suggesting that decreases in ANF degradation, rather than
hemodynamically-mediated increases in ANF secretion, were
responsible.
The natriuresis observed following NEP-I in the present
study occurred without significant increases in GFR or renal
blood flow. In previous studies by Ura, Carretero and Erdös
[24], the natriuresis produced by phosphoramidon in normal
rats similarly occurred in the absence of any significant changes
in GFR or renal blood flow. However, the increase in filtration
fraction in the CK and the tendency for an increase in the SK
indicate that NEP-I may be influencing glomerular dynamics,
either the ultrafiltration coefficient (Kf) or efferent arteriolar
resistance. Furthermore, recent studies by Mejia et al [27]
demonstrate that small (for example, 5%) changes in GFR,
which may escape detection by usual clearance methods, can
produce significant increases in sodium excretion independent
of changes in tubular reabsorption. Thus, while NEP-I ap-
peared to decrease tubular sodium reabsorption in the present
study, we cannot exclude subtle changes in GFR as well,
particularly in the presence of physiologic levels of ANF. In
this regard, the renal action of NEP-I mimics the renal action of
P < 0.053
300
. 200
>
Z 100
-1
0
6
4
zwU-
2
0
CK SK
Fig. 1. Absolute increases in urine flow, absolute sodium excretion
(UN,V) and fractional sodium excretion (FEN,,) in response to neutral
endopeptidase inhibition (SQ 28,603) in the control kidney (CK) ex-
posed to physiologic concentrations of ANF and the supplemented
kidney (SK) exposed to pathophysiologic concentrations of ANF.
SK
P< 0.05
1
CK
P < 0.05
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low-dose intrarenal ANF infusion. Importantly, the renal action
of NEP-I occurs at a lower renal plasma ANF concentration as
compared to exogenous ANF. Such an observation is consis-
tent with potentiation of ANF by NEP-I.
Following NEP-I we observed significant increases in FENa
in both CK and SK, indicating decreases in tubular reabsorp-
tion of filtered sodium. The lack of significant increases in FELl
further suggests that the major impact of NEP-I on tubular
sodium handling occurred beyond the proximal tubule. Previ-
ous studies have demonstrated specific membrane-bound re-
ceptors for ANF at the inner-medullary collecting duct (IMCD)
[28—30]. ANF action at the IMCD is linked to generation of
cGMP [31—33] which, in turn, attenuates osmotic water perme-
ability [33]. Moreover, Zeidel et al [34] have demonstrated that
ANF modulates apical sodium uptake in IMCD cells via inhi-
bition of amiloride-sensitive sodium channels in association
with cGMP generation. In the present study, increases in FENa
following NEP-I were associated with increases in urinary
cGMP in both CK and SK and decreases in urine osmolality,
findings compatible with enhanced ANF action at the IMCD.
Marked increases in total urinary excretion of ANF were
observed following NEP-I in this study. This finding likely
reflects both modest increases in circulating ANF and de-
creases in renal ANF degradation. Shima et al [9] have demon-
strated that proximal tubule brush borders and glomeruli have
the greatest ANF degrading capacity. Therefore, increased
urinary ANF recovery may, in part, reflect decreased degrada-
tion in the proximal nephron. Of interest, fractional excretion of
ANF, a marker for tubular handling of ANF, actually decreased
during infusion of ANF in the SK. This finding is consistent
with the non-saturable nature of the brush border neutral
endopeptidase as demonstrated by Berg et al [35]. However,
following NEP-I, fractional excretion of ANF increased in both
CK and SK, suggesting that decreases in tubular degradation of
ANF contributed to increases in urinary recovery of ANF.
While increased distal nephron delivery of ANF may contribute
to the observed natriuresis, alternative mechanisms must be
considered. Such alternative mechanisms for natriuresis follow-
ing NEP-I and/or ANF include increases in ANF binding at the
basolateral membrane of IMCD cells, changes in intrarenal
physical forces or increases in medullary blood flow which
might explain the significant decreases in urine osmolality
observed following NEP-I.
The NEP-I used in this study, SQ 28,603, has minimal
activity against other proximal tubule brush border enzymes,
including angiotensin converting enzyme and aminopeptidase
M. However, the activity of the compound against other
peptidases outside the brush border are undefined. In addition
to ANF, neutral endopeptidase hydrolyzes other peptides in
vitro including kinins, angiotensins, enkephalins, neurotensin,
substance P, insulin 13-chain and endothelin [4, 36, 37]. In the
present study, decreases in degradation of non-ANF peptides,
particularly kinins, could have contributed to natriuresis follow-
ing NEP-I. However, the increased urinary cGMP excretion
and potentiated natriuresis in the presence of pathophysiologic
levels of ANF suggest that NEP-I enhances sodium excretion
predominantly by blocking ANF degradation. Thus, NEP-I
may be most effective in states with elevated levels of endoge-
nous ANF, like congestive heart failure and hypertension. On
the other hand, observed increases in systemic and renal
vascular resistances following NEP-I might be related to de-
creased neutral peptidase degradation of vasoconstrictor pep-
tides, including angiotensins and endothelin.
In conclusion, this study demonstrates, for the first time, the
renal responses to administration of an inhibitor of neutral
endopeptidase in the presence of physiologic and pathophysio-
logic concentrations of ANF in normal anesthetized dogs. The
major finding is that NEP-I produces significant increases in
sodium and water excretion which are independent of signifi-
cant changes in GFR or renal blood flow. The enhanced urinary
ANF and cGMP excretion, known cGMP-linked action of ANF
at the medullary collecting duct, and enhanced diuresis and
natriuresis observed in response to administration of patho-
physiologic concentrations of ANF all suggest that NEP-I
induces sodium excretion primarily by decreasing degradation
of ANF. Further, the enhanced natriuresis following NEP-I in
the kidney supplemented with pathophysiologic concentrations
of ANF support the speculation that NEP-I might potentiate the
renal actions of ANF in congestive heart failure or hyperten-
sion.
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